Tajikistan Medical Device Registration: Certificate of Free Sale and Country of Origin Proof

1. Key takeaways

In a Tajik registration dossier, proof of market authorization in the country of origin, typically a Certificate of Free Sale, is the first threshold. Article 17(2) of Law No. 1893 requires the applicant to submit the prescribed list of necessary documents, and the content of that list is developed and approved by the authorized state body in the healthcare sector under Article 17(12). GRZAN notes that Law No. 1893 does not expressly list proof of origin-country marketing at the statutory level, but the necessity of this document can be derived from three legal threads: the list authorization in Article 17(2), the five-dimensional review standard of Article 18(1), and the institutional arrangement for recognizing foreign standards in Article 8(17).

2. Legal basis

3. Expert insights

Insight 1: The legal function of proof of origin-country marketing is to convert the fact that the product is lawful in its home market into evidence admissible in Tajikistan. Article 17(2) delegates the determination of the document list to Ministry of Health procedural documents, while the five-dimensional review of Article 18(1) requires the reviewing authority to evaluate safety and effectiveness. For a foreign product, the most direct evidence is that it has already been approved for marketing in its country of manufacture. The GRZAN judgment is that proof of origin-country marketing is the supporting document for the safety and effectiveness dimensions of the five-dimensional review, and its position is equivalent to the foundation of the entire evidence chain.

Insight 2: Article 8(17) provides the institutional channel for admitting foreign approval documents. The provision states that the Ministry of Health may, where necessary, recognize the pharmacopoeias and quality standards of other countries for medicines and medical products. Although the text directly addresses standards rather than approval decisions, it establishes a principle: the Tajik authorities have the power to recognize foreign technical judgments. When submitting proof of origin-country marketing, companies may cite this provision as the basis for admissibility and attach a standards comparison as supporting material.

Insight 3: Article 16(7) anchors the determination of quality requirements to the documents on which registration was granted. The provision states that the quality requirements for medical products and quasi-medicinal products apply according to the quality specification documents, technical conditions and other standards on the basis of which they passed state registration. The meaning is that quality requirements are fixed at registration, and subsequent batch-by-batch conformity assessment under Article 13(1) uses this record as the benchmark. Quality documents accepted at registration therefore become a long-term constraint, and companies must draft them with care at the outset.

Insight 4: A Chinese NMPA registration certificate and a Certificate of Free Sale are two documents of different natures and must be prepared separately. Chinese manufacturers frequently conflate the two. The GRZAN approach is: the NMPA registration certificate proves the product has been approved for marketing in China, corresponding to proof of origin-country marketing; the Certificate of Free Sale, issued by the provincial medical products administration, proves the product is freely sold within China. Their functions differ, and preparing both simultaneously is recommended to satisfy the differing requirements that may appear in Tajik procedural documents.

Insight 5: The international cooperation clause of Article 46(2) can serve as a framing basis in communications. The provision states that Tajikistan conducts international cooperation in the development, production, quality control and trade of medicines, medical products and quasi-medicinal products, including the exchange of information, advanced methods and technologies. In communications concerning the admissibility of foreign approval documents, this provision may be cited as the framework for cooperation, but companies should note that it does not produce any automatic effect of recognition; each case still requires the authorities to accept the foreign evidence.

4. Practical recommendations

1. Prepare both the origin-country registration certificate and the Certificate of Free Sale. GRZAN recommends that Chinese manufacturers treat the NMPA registration certificate and the Certificate of Free Sale issued by the provincial medical products administration as two independent documents, each with its own notarization, legalization and translation.
2. Attach a standards comparison as supporting material. Under Article 8(17), prepare a comparison statement mapping Chinese standards item by item against Tajik requirements, serving as the technical argument for admitting the foreign documents.
3. Verify the validity period and coverage of the certificates. After obtaining the documents, check that the issue date falls within a reasonable period, that the product names and models match the registration application, and that the coverage includes all models intended for registration.
4. Treat the drafting of quality documents as a long-term constraint. Under Article 16(7), the quality documents submitted at registration become the benchmark for subsequent batch-by-batch conformity assessment. Introduce a cross-functional review at the drafting stage to avoid setting standards the company cannot later meet.
5. Establish a trigger mechanism for certificate updates. When the origin-country registration certificate is amended, renewed or cancelled, assess in parallel whether a corresponding change filing must be made to the Tajik authorities under Article 17(12).

5. Verification checklist

• □ Both the origin-country registration certificate and the Certificate of Free Sale have been prepared as independent documents
• □ Notarization, legalization and translation have been completed for both documents
• □ Consistency of issue dates, covered models and the registration application has been verified
• □ A standards comparison has been attached, citing the recognition pathway of Article 8(17)
• □ The cross-functional review of quality documents has been completed to the standard of Article 16(7)
• □ A trigger mechanism for filing Tajik-side changes after origin-country certificate amendments has been established (Article 17(12))
• □ The current procedural documents have been requested to confirm whether proof of origin-country marketing is a mandatory item (Article 17(2))

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com